Loading...
Loading...
Celgene International Sàrl, a subsidiary of Celgene Corporation
CELG
today announced that its phase III study of ABRAXANE^® (paclitaxel
protein-bound particles for injectable suspension) (albumin-bound) in
combination with gemcitabine in treatment-naïve patients with advanced
pancreatic cancer met its primary endpoint of overall survival. In the study,
ABRAXANE in combination with gemcitabine demonstrated a statistically
significant improvement in overall survival compared to patients receiving
gemcitabine alone.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in